Unicycive Therapeutics (UNCY) Q3 2024 earnings summary

Executive summary

• Net loss for the nine months ended September 30, 2024 was $15.2 million, a 33% improvement year-over-year, with an accumulated deficit of $79.7 million as of September 30, 2024.

• FDA accepted NDA for oxylanthanum carbonate (OLC) with a PDUFA target action date of June 28, 2025, and commercial launch planning underway for 2025.

• Raised $50 million in gross proceeds through a private placement of Series B-1 Convertible Preferred Stock in March 2024, with subsequent conversion to common and Series B-2 preferred shares.

• Successful completion of UNI-494 Phase 1 trial; plans to advance to Phase 2 for acute kidney injury.

• OLC pivotal trial showed strong patient preference and satisfaction compared to prior therapies.

Financial highlights

• Research and development expenses rose 70% year-over-year to $14.7 million for the nine months ended September 30, 2024, mainly due to increased drug development costs.

• General and administrative expenses increased 26% to $8.1 million for the same period, driven by higher stock compensation, labor, and other costs.

• Other income (expenses) improved by $15.5 million, primarily due to a favorable change in fair value of warrant liability.

• Cash and cash equivalents were $32.3 million as of September 30, 2024, up from $9.7 million at December 31, 2023, and expected to fund operations into 2026.

• Net loss attributable to common stockholders was $4.1 million for Q3 2024, compared to $4.4 million in Q3 2023.

Outlook and guidance

• Management expects continued operating losses and negative cash flows as research and development activities increase.

• Sufficient resources are available to fund operations for at least one year, with cash expected to support operations into 2026, but additional capital will be needed for future clinical trials and commercialization.

• Preparing for potential OLC commercial launch in the second half of 2025, pending FDA approval.

• The company is actively seeking further equity, debt, or collaborative financing.

• Plans to meet with FDA by year-end to advance UNI-494 to Phase 2 clinical development.